Search

Displaying results 2261 - 2270 of 10000 in total
  1. Drug

    Revefenacin

    go.drugbank.com/drugs/DB11855
    ApprovedInvestigational

    The labile primary amide in the structure produces a "soft-drug" site that allows rapid systemic clearance and minimizing of the systemically mediated adverse reactions. … [A40026] It was developed by Theravance Biopharma and FDA approved on November 9, 2018.[L4818]

  2. Drug

    Fidaxomicin

    go.drugbank.com/drugs/DB08874
    ApprovedInvestigational

    [A190501] Because fidaxomicin contains an 18-membered lactone ring in its structure, it is referred to as a macrocyclic lactone antibiotic drug. … [A190492] Unlike vancomycin, however, fidaxomicin has a negligible effect on normal colonic microflora.

  3. Drug

    Resmetirom

    go.drugbank.com/drugs/DB12914
    ApprovedInvestigational

    On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD … Resmetirom is a thyroid hormone receptor-beta (THR-beta) agonist.

  4. Drug

    Metrizoic acid

    go.drugbank.com/drugs/DB09346
    Approved

    In general, the drug was well tolerated by patients during cardiac examinations [A32091]. … One study in 1976 demonstrated that metrizoic acid, when used for cardiac angiography, was well tolerated.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Atacicept

    go.drugbank.com/drugs/DB06399
    ApprovedInvestigational

    [L63797,L63928] The approval is conditional on a proven reduction of proteinuria in the Origin 3 trial, which is evaluating whether the atacicept slows long-term kidney function decline. … factor (BAFF) and A Proliferation Inducing Ligand (APRIL).

  6. Drug

    Betibeglogene autotemcel

    go.drugbank.com/drugs/DB16900
    ApprovedInvestigational

    Betibeglogene autotemcel is an autologous gene therapy that adds functional copies of the β-globin gene (β<sup>A-T87Q</sup>-globin) to hematopoietic stem cells in order to treat β-thalassemia. … [L42940] β-thalassemia is a condition caused by mutations in the β-globin gene (HBB) that leads to a significant decrease in the production of β-globin.

    Synonyms: Autologous CD34+ cells encoding βA-T87Q-Globin gene
  7. Drug

    Diclofenamide

    go.drugbank.com/drugs/DB01144
    Approved

    A carbonic anhydrase inhibitor that is used in the treatment of glaucoma.

  8. Drug

    Conivaptan

    go.drugbank.com/drugs/DB00872
    Approved

    Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). … It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH).

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: Vaprisol Dextrose In Plastic Container
  9. Drug

    Belatacept

    go.drugbank.com/drugs/DB06681
    ApprovedInvestigational

    It is produced through recombinant DNA technology in mammalian CHO cells. The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. … FDA approved on June 15, 2011.

  10. Drug

    Demecarium

    go.drugbank.com/drugs/DB00944
    Approved

    Demecarium is an indirect-acting parasympathomimetic agent that is used to treat glaucoma. It is a cholinesterase inhibitor or an anticholinesterase. … The outflow of the aqueous humor is facilitated, which leads to a reduction in intraocular pressure.